epidemiologyЭпидемиология и ВакцинопрофилактикаEpidemiology and Vaccinal Prevention2073-30462619-0494«Numicom» LLC10.31631/2073-3046-2020-19-6-69-73epidemiology-1127Research ArticleПРАКТИЧЕСКИЕ АСПЕКТЫ ЭПИДЕМИОЛОГИИ И ВАКЦИНОПРОФИЛАКТИКИPRACTICAL ASPECTS OF EPIDEMIOLOGY AND VACCINE PREVENTIONЭпидемиологическое значение бессимптомных носителей COVID-19Epidemiological Significance of Asymptomatic Carriers of COVID-19https://orcid.org/0000-0002-5695-6752БазыкинаЕ. А.BazykinaE. A.

Базыкина Елена Анатольевна - младший научный сотрудник Хабаровского НИИ эпидемиологии и микробиологии.Хабаровск.Тел. +7 (4212) 46-18-55

Bazykina Elena A. - junior research of Khabarovsk research institute of epidemiology and microbiology.Khabarovsk.Tel. +7 (4212) 46-18-55

alyonaf@yandex.ruhttps://orcid.org/0000-0003-3050-4472ТроценкоО. Е.TrotsenkoO. E.

Троценко Ольга Евгеньевна – доктор медицинских наук, директор Хабаровского НИИ эпидемиологии и микробиологии.Хабаровск.Тел. +7(4212)32-52-28

Olga E. Trotsenko - Dr. Sci. (Med.), director of Khabarovsk research institute of epidemiology and microbiology.Khabarovsk.Tel. +7 (4212) 32-52-28

Хабаровский научно-исследовательский институт эпидемиологии и микробиологии РоспотребнадзораРоссияKhabarovsk research institute of epidemiology and microbiology of the Federal service for surveillance on consumers rights protection and human wellbeingRussian Federation2020130120211966973Copyright © Базыкина Е.А., Троценко О.Е., 20212021Базыкина Е.А., Троценко О.Е.Bazykina E.A., Trotsenko O.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epidemvac.ru/jour/article/view/1127

Актуальность. Пандемия новой коронавирусной инфекции является серьезным испытанием для мировой системы здравоохранения, а контроль за развитием эпидемического процесса одна из главных задач в борьбе с COVID-19. Цель. По данным зарубежной литературы оценить роль бессимптомных носителей COVID-19 в эпидемическом процессе новой коронавирусной инфекции. Выводы. Показано менее стойкое формирование иммунного ответа у лиц с бессимптомной формой заболевания по сравнению клиническими формами инфекции COVID-19. Для выяснения аспектов патогенетического процесса и установления реальной стойкости иммунного ответа помимо исследования гуморального иммунного ответа целесообразно изучение клеточного звена иммунитета, в особенности клеток памяти у лиц, перенесших COVID-19. С целью подбора наиболее оптимальных противоэпидемических мер для сдерживания дальнейшего распространения заболевания, в том числе бессимптомного носительства необходимо установление индекса репродукции и определение минимальной инфицирующей дозы SARS-CoV-2.

Relevance. Pandemic of the new coronavirus infection has become a challenging issue for world healthcare system. Control of the epidemic process is one of the main priorities in combat against new coronavirus disease Aim. The research highlights the issue of asymptomatic carriers of the new coronavirus disease. Conclusions. It was revealed that patients with asymptomatic form of COVID-19 have a less lasting immunity response compared with those that have had clinically active forms of the infection. In order to determine pathogenetic process and fully understand formation of the immune response, it is necessary to study both humoral and cellular immune responses in patients diagnosed with COVID-19. In order to select most optimal anti-epidemic measures to contain the further spread of the disease, including asymptomatic carriage, it is necessary to establish SARS-CoV-2 reproduction index and determine minimal infective dose of SARS-CoV-2.

SARS-CoV-2бессимптомное носительствоэпидемиологияпандемияSARS-CoV-2asymptomatic carriersepidemiologypandemicReferencesAl-Tawfiq JA. Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19). Travel Med Infect Dis. 2020;35:101608. doi:10.1016/j.tmaid.2020.101608.Al-Tawfiq JA. Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19). Travel Med Infect Dis. 2020;35:101608. doi:10.1016/j.tmaid.2020.101608.Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol immunol infect. 2020;53(3):404-412. doi:10.1016/j.jmii.2020.02.012.Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol immunol infect. 2020;53(3):404-412. doi:10.1016/j.jmii.2020.02.012.Gao Z, Xu Y, Sun C, et al. A Systematic Review of Asymptomatic Infections with COVID-19. J Microbiol Immunol Infect. 2020;10.1016/j.jmii.2020.05.001. doi:10.1016/j.jmii.2020.05.001Gao Z, Xu Y, Sun C, et al. A Systematic Review of Asymptomatic Infections with COVID-19. J Microbiol Immunol Infect. 2020;10.1016/j.jmii.2020.05.001. doi:10.1016/j.jmii.2020.05.001Wu ZY. Contribution of asymptomatic and pre-symptomatic cases of COVID-19 in spreading virus and targeted control strategies. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(6):801-805. Chinese. doi: 10.3760/cma.j.cn112338-20200406-00517. PMID: 32274917.Wu ZY. Contribution of asymptomatic and pre-symptomatic cases of COVID-19 in spreading virus and targeted control strategies. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(6):801-805. Chinese. doi: 10.3760/cma.j.cn112338-20200406-00517. PMID: 32274917.Wu Z, McGoogan JM. Asymptomatic and Pre-Symptomatic COViD-19 in China. infect Dis Poverty. 2020;9(1):72. doi:10.1186/s40249-020-00679-2.Wu Z, McGoogan JM. Asymptomatic and Pre-Symptomatic COViD-19 in China. infect Dis Poverty. 2020;9(1):72. doi:10.1186/s40249-020-00679-2.Huff HV, Singh A. Asymptomatic transmission during the COViD-19 pandemic and implications for public health strategies. Clin infect Dis. 2020;ciaa654. doi:10.1093/cid/ciaa654.Huff HV, Singh A. Asymptomatic transmission during the COViD-19 pandemic and implications for public health strategies. Clin infect Dis. 2020;ciaa654. doi:10.1093/cid/ciaa654.Lin C, Ding Y, Xie B, et al. Asymptomatic novel coronavirus pneumonia patient outside Wuhan: The value of CT images in the course of the disease. Clin imaging. 2020;63:7-9. doi:10.1016/j.clinimag.2020.02.008.Lin C, Ding Y, Xie B, et al. Asymptomatic novel coronavirus pneumonia patient outside Wuhan: The value of CT images in the course of the disease. Clin imaging. 2020;63:7-9. doi:10.1016/j.clinimag.2020.02.008.Castanheira J, Mascarenhas Gaivao A, Mairos Teixeira S, et al. Asymptomatic COViD-19 positive patient suspected on FDG-PET/CT. Nucl Med Commun. 2020;41(6):598-599. doi:10.1097/MNM.0000000000001221.Castanheira J, Mascarenhas Gaivao A, Mairos Teixeira S, et al. Asymptomatic COViD-19 positive patient suspected on FDG-PET/CT. Nucl Med Commun. 2020;41(6):598-599. doi:10.1097/MNM.0000000000001221.Albano D, Bertagna F, Bertoli M, et al. incidental Findings Suggestive of COVID-19 in Asymptomatic Patients Undergoing Nuclear Medicine Procedures in a High-Prevalence Region. J Nucl Med. 2020;61(5):632-636. doi:10.2967/jnumed.120.246256.Albano D, Bertagna F, Bertoli M, et al. incidental Findings Suggestive of COVID-19 in Asymptomatic Patients Undergoing Nuclear Medicine Procedures in a High-Prevalence Region. J Nucl Med. 2020;61(5):632-636. doi:10.2967/jnumed.120.246256.Meng H, Xiong R, He R, et al. CT imaging and clinical course of asymptomatic cases with COViD-19 pneumonia at admission in Wuhan, China. J infect. 2020;81(1):e33-e39. doi:10.1016/j.jinf.2020.04.004.Meng H, Xiong R, He R, et al. CT imaging and clinical course of asymptomatic cases with COViD-19 pneumonia at admission in Wuhan, China. J infect. 2020;81(1):e33-e39. doi:10.1016/j.jinf.2020.04.004.Yu X, Yang R. COViD-19 transmission through asymptomatic carriers is a challenge to containment. influenza Other Respir Viruses. 2020;14(4):474-475. doi:10.1111/irv.12743.Yu X, Yang R. COViD-19 transmission through asymptomatic carriers is a challenge to containment. influenza Other Respir Viruses. 2020;14(4):474-475. doi:10.1111/irv.12743.Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 infection: A Narrative. Ann intern Med. 2020;M20-3012. doi:10.7326/M20-3012.Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 infection: A Narrative. Ann intern Med. 2020;M20-3012. doi:10.7326/M20-3012.Hosoki K, Chakraborty A, Sur S. Molecular mechanisms and epidemiology of COViD-19 from an allergist's perspective. J Allergy C!in immuno!. 2020;S0091-6749(20)30799-5. doi:10.1016/j.jaci.2020.05.033.Hosoki K, Chakraborty A, Sur S. Molecular mechanisms and epidemiology of COViD-19 from an allergist's perspective. J Allergy C!in immuno!. 2020;S0091-6749(20)30799-5. doi:10.1016/j.jaci.2020.05.033.Wei L, Lin J, Duan X, et al. Asymptomatic COViD-19 Patients Can Contaminate Their Surroundings: an Environment Sampling Study. mSphere. 2020;5(3):e00442-20. doi:10.1128/mSphere.00442-20.Wei L, Lin J, Duan X, et al. Asymptomatic COViD-19 Patients Can Contaminate Their Surroundings: an Environment Sampling Study. mSphere. 2020;5(3):e00442-20. doi:10.1128/mSphere.00442-20.Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020;323(14):1406-1407. doi:10.1001/jama.2020.2565;Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020;323(14):1406-1407. doi:10.1001/jama.2020.2565;Huang L, Zhang X, Zhang X, et al. Rapid asymptomatic transmission of COViD-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COViD-19: A prospective contact-tracing study. J infect. 2020;80(6):e1-e13. doi:10.1016/j.jinf.2020.03.006.Huang L, Zhang X, Zhang X, et al. Rapid asymptomatic transmission of COViD-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COViD-19: A prospective contact-tracing study. J infect. 2020;80(6):e1-e13. doi:10.1016/j.jinf.2020.03.006.Ye F, Xu S, Rong Z, et al. De!ivery of infection from asymptomatic carriers of COViD-19 in a familial cluster. int J infect Dis. 2020;94:133-138. doi:10.1016/j.ijid.2020.03.042.Ye F, Xu S, Rong Z, et al. De!ivery of infection from asymptomatic carriers of COViD-19 in a familial cluster. int J infect Dis. 2020;94:133-138. doi:10.1016/j.ijid.2020.03.042.Pan X, Chen D, Xia Y, et al. Asymptomatic cases in a family cluster with SARS-CoV-2 infection. Lancet Infect Dis. 2020;20(4):410-411. doi:10.1016/S1473-3099(20)30114-6юPan X, Chen D, Xia Y, et al. Asymptomatic cases in a family cluster with SARS-CoV-2 infection. Lancet Infect Dis. 2020;20(4):410-411. doi:10.1016/S1473-3099(20)30114-6юGao M, Yang L, Chen X, et al. A study on infectivity of asymptomatic SARS-CoV-2 carriers. Respir Med. 2020;169:106026. doi:10.1016/j.rmed.2020.106026Gao M, Yang L, Chen X, et al. A study on infectivity of asymptomatic SARS-CoV-2 carriers. Respir Med. 2020;169:106026. doi:10.1016/j.rmed.2020.106026He D, Zhao S, Lin Q, et al. The relative transmissibility of asymptomatic COViD-19 infections among close contacts. int J infect Dis. 2020;94:145-147. doi:10.1016/j.ijid.2020.04.034.He D, Zhao S, Lin Q, et al. The relative transmissibility of asymptomatic COViD-19 infections among close contacts. int J infect Dis. 2020;94:145-147. doi:10.1016/j.ijid.2020.04.034.Chen Y, Wang A, Yi B, et al. The epidemiological characteristics of infection in close contacts of COViD-19 in Ningbo city. Chin J Epidemiol. 2020:41.Chen Y, Wang A, Yi B, et al. The epidemiological characteristics of infection in close contacts of COViD-19 in Ningbo city. Chin J Epidemiol. 2020:41.Miyamae Y, Hayashi T, Yonezawa H, et al. Duration of viral shedding in asymptomatic or mild cases of novel coronavirus disease 2019 (COVID-19) from a cruise ship: A singlehospital experience in Tokyo, Japan. int J infect Dis. 2020;97:293-295. doi:10.1016/j.ijid.2020.06.020.Miyamae Y, Hayashi T, Yonezawa H, et al. Duration of viral shedding in asymptomatic or mild cases of novel coronavirus disease 2019 (COVID-19) from a cruise ship: A singlehospital experience in Tokyo, Japan. int J infect Dis. 2020;97:293-295. doi:10.1016/j.ijid.2020.06.020.Li W, Su YY, Zhi SS, et al. Viral shedding dynamics in asymptomatic and mildly symptomatic patients infected with SARS-CoV-2. Clin Microbiol infect. 2020;S1198-743X(20)30410-9. doi:10.1016/j.cmi.2020.07.008.Li W, Su YY, Zhi SS, et al. Viral shedding dynamics in asymptomatic and mildly symptomatic patients infected with SARS-CoV-2. Clin Microbiol infect. 2020;S1198-743X(20)30410-9. doi:10.1016/j.cmi.2020.07.008.Wu Z, McGoogan JM. Asymptomatic and Pre-Symptomatic COViD-19 in China. infect Dis Poverty. 2020;9(1):72. doi:10.1186/s40249-020-00679-2.Wu Z, McGoogan JM. Asymptomatic and Pre-Symptomatic COViD-19 in China. infect Dis Poverty. 2020;9(1):72. doi:10.1186/s40249-020-00679-2.National Health Commission of the People's Republic of China. Update on COVID-19 in China as of 24th hour on April 7,2020. Beijing, China: National Health Commission;2020.National Health Commission of the People's Republic of China. Update on COVID-19 in China as of 24th hour on April 7,2020. Beijing, China: National Health Commission;2020.Kim GU, Kim MJ, Ra SH, et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin Microbiol infect. 2020;26(7):948.e1-948.e3. doi:10.1016/j.cmi.2020.04.040.Kim GU, Kim MJ, Ra SH, et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin Microbiol infect. 2020;26(7):948.e1-948.e3. doi:10.1016/j.cmi.2020.04.040.Pollan M, Pёrez-Gбmez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;S0140-6736(20)31483-5. doi:10.1016/S0140-6736(20)31483-5.Pollan M, Pёrez-Gбmez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;S0140-6736(20)31483-5. doi:10.1016/S0140-6736(20)31483-5.Gallian P, Pastorino B, Morel P, et al. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood. Antiviral Res. 2020;181:104880. doi:10.1016/j.antiviral.2020.104880.Gallian P, Pastorino B, Morel P, et al. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood. Antiviral Res. 2020;181:104880. doi:10.1016/j.antiviral.2020.104880.Rivett L, Sridhar S, Sparkes D, et al. Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. Elife. 2020;9:e58728. doi:10.7554/eLife.58728.Rivett L, Sridhar S, Sparkes D, et al. Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. Elife. 2020;9:e58728. doi:10.7554/eLife.58728.Korth J, Wilde B, Dolff S, et al. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. J Clin Virol. 2020;128:104437. doi:10.1016/j.jcv.2020.104437.Korth J, Wilde B, Dolff S, et al. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. J Clin Virol. 2020;128:104437. doi:10.1016/j.jcv.2020.104437.Schmidt SB, Grdter Boltzmann M, Rollnik JD. Prevalence of serum IgG antibodies against SARS-CoV-2 among clinic staff. PLoS One. 2020;15(6):e0235417. doi:10.1371/journal.pone.0235417.Schmidt SB, Grdter Boltzmann M, Rollnik JD. Prevalence of serum IgG antibodies against SARS-CoV-2 among clinic staff. PLoS One. 2020;15(6):e0235417. doi:10.1371/journal.pone.0235417.Garcia-Basteiro AL, Moncunill G, Tortajada M, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020;11(1):3500. doi:10.1038/s41467-020-17318-x.Garcia-Basteiro AL, Moncunill G, Tortajada M, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020;11(1):3500. doi:10.1038/s41467-020-17318-x.Corradini P, Gobbi G, de Braud F, et al. Rapid Antibody Testing for SARS-CoV-2 in Asymptomatic and Paucisymptomatic Healthcare Professionals in Hematology and Oncology Units Identifies Undiagnosed Infections. Hemasphere. 2020;4(3):e408. doi:10.1097/HS9.0000000000000408.Corradini P, Gobbi G, de Braud F, et al. Rapid Antibody Testing for SARS-CoV-2 in Asymptomatic and Paucisymptomatic Healthcare Professionals in Hematology and Oncology Units Identifies Undiagnosed Infections. Hemasphere. 2020;4(3):e408. doi:10.1097/HS9.0000000000000408.Patel MC, Chaisson LH, Borgetti S, et al. Asymptomatic SARS-CoV-2 infection and COVID-19 mortality during an outbreak investigation in a skilled nursing facility. Clin Infect Dis. 2020;ciaa763. doi:10.1093/cid/ciaa763.Patel MC, Chaisson LH, Borgetti S, et al. Asymptomatic SARS-CoV-2 infection and COVID-19 mortality during an outbreak investigation in a skilled nursing facility. Clin Infect Dis. 2020;ciaa763. doi:10.1093/cid/ciaa763.Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19. N Engl J Med. 2020;382(22):2158-2160. doi:10.1056/NEJMe2009758.Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19. N Engl J Med. 2020;382(22):2158-2160. doi:10.1056/NEJMe2009758.Nahshon C, Bitterman A, Haddad R, et al. Hazardous Postoperative Outcomes of Unexpected COVID-19 Infected Patients: A Call for Global Consideration of Sampling all Asymptomatic Patients Before Surgical Treatment. World J Surg. 2020;44(8):2477-2481. doi:10.1007/s00268-020-05575-2.Nahshon C, Bitterman A, Haddad R, et al. Hazardous Postoperative Outcomes of Unexpected COVID-19 Infected Patients: A Call for Global Consideration of Sampling all Asymptomatic Patients Before Surgical Treatment. World J Surg. 2020;44(8):2477-2481. doi:10.1007/s00268-020-05575-2.Siracusano G, Pastori C, Lopalco L. Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art. Front Immunol. 2020;11:1049. doi:10.3389/fimmu.2020.01049.Siracusano G, Pastori C, Lopalco L. Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art. Front Immunol. 2020;11:1049. doi:10.3389/fimmu.2020.01049.Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;10.1038/s41591-020-0965-6. doi:10.1038/s41591-020-0965-6.Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;10.1038/s41591-020-0965-6. doi:10.1038/s41591-020-0965-6.Choe PG, Kang CK, Suh HJ, et al. Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients. Emerg Infect Dis. 2020;26(10):10.3201/ eid2610.202211. doi:10.3201/eid2610.202211.Choe PG, Kang CK, Suh HJ, et al. Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients. Emerg Infect Dis. 2020;26(10):10.3201/ eid2610.202211. doi:10.3201/eid2610.202211.Siracusano G, Pastori C, Lopalco L. Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art. Front Immunol. 2020;11:1049. doi:10.3389/fimmu.2020.01049.Siracusano G, Pastori C, Lopalco L. Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art. Front Immunol. 2020;11:1049. doi:10.3389/fimmu.2020.01049.Spiegel, M., Pichlmair, A., Martfnez-Sobrido, L., et al. Inhibition of Beta interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3. J Virol 2005. 79: 2079-2086.Spiegel, M., Pichlmair, A., Martfnez-Sobrido, L., et al. Inhibition of Beta interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3. J Virol 2005. 79: 2079-2086.Gralinski LE, Sheahan TP, Morrison TE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio Oct 2018, 9 (5) e01753-18. doi:10.1128/mBio.01753-18.Gralinski LE, Sheahan TP, Morrison TE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio Oct 2018, 9 (5) e01753-18. doi:10.1128/mBio.01753-18.Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. Sci Immunol. 2020;5(49):eabd6160. doi:10.1126/sciimmunol.abd6160.Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. Sci Immunol. 2020;5(49):eabd6160. doi:10.1126/sciimmunol.abd6160.

The authors declare that there are no conflicts of interest present.